Sample
Serum, Plasma, and Dried Fecal Samples, or Urine and Tissue Culture Media
Species Reactivity
Universal
Intended Use
The Allopregnanolone ELISA Kits measure allopregnanolone in a variety of samples.
Contents of Kit
1. Coated Clear 96 Well Plates:
Clear plastic microtiter plate(s) coated with goat anti-mouse IgG.
2. Allopregnanolone Standard:
Allopregnanolone at 100,000 pg/mL in a special stabilizing solution. 125 μL
3. Allopregnanolone Antibody: Must be stored at -20°C.
A mouse monoclonal antibody speciffc for allopregnanolone. 3 mL
4. Allopregnanolone Conjugate: Must be stored at -20°C.
Allopregnanolone-peroxidase conjugate in a special stabilizing solution. 3 mL
5. Assay Buffer Concentrate:
The kit uses a 5× concentrate that should be diluted with deionized or distilled water. 28 mL
6. Wash Buffer Concentrate:
A 20× concentrate that should be diluted with deionized or distilled water. 30 mL
7. TMB Substrate: 11 mL
8. Stop Solution: A 1M solution of hydrochloric acid. 5 mL
9. Plate Sealer:
Storage
The unopened kit must be stored at -20°C.
Once opened the kit can be stored at 4°C up to the expiration date on the kit label, except for the Allopregnanolone Antibody and Conjugate which must be stored at -20°C. The frozen Allopregnanolone Conjugate can be freeze-thawed multiple times
Precision
Intra Assay Precision:Three mammalian samples were diluted with Assay Buffer and run in replicates of 20 in an assay. The mean and precision of the calculated allopregnanolone concentrations were:
Inter Assay Precision:Three mammalian samples were diluted with Assay Buffer and run in duplicates in twenty assays run over multiple days by four operators. The mean and precision of the calculated allopregnanolone concentrations were:
Detection Limit
The Limit of Detection for the assay was determined in a similar manner by comparing the OD' s for twenty runs for each of the zero standard and a low concentration mammalian sample. Limit of Detection was determined as 65.9 pg/mL
Sensitivity
Sensitivity was calculated by comparing the OD's for nineteen wells run for each of the B0 and standard #7. The detection limit was determined at two (2) standard deviations from the B0 along the standard curve.Sensitivity was determined as 129.7 pg/mL.
General Description
Allopregnanolone is a naturally occurring neurosteroid which is made in the body from the hormone progesterone. As a medication, allopregnanolone was referred to as brexanolone, sold under the brand name Zulresso, and was used to treat postpartum depression. It was given by injection into a vein.
Side effects of brexanolone may include sedation, sleepiness, dry mouth, hot flashes, and loss of consciousness. It was a neurosteroid and acts as a positive allosteric modulator of the GABAA receptor, the major biological target of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).
Brexanolone was approved for medical use in the United States in 2019 and withdrawn from approval in 2025. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.The long administration time, as well as the cost for a one-time treatment, have raised concerns about accessibility for many women.
Allopregnanolone aids neurogenesis and has been found to reverse neuron proliferative deffcit and cognitive deffcits in a mouse model of Alzheimer's disease. Allopregnanolone has also been shown to restore functionality in a mouse model of Parkinson's Disease and to improve behavioral problems in post-traumatic stress disorder.
Standard Curve

Always run your own standard curve for calculation of results. Do not use this data. Conversion Factor: 1 pg/mL of allopregnanolone is equivalent to 3.14 pM.

Always run your own standard curves for calculation of results. Do not use this data.
Citations
Have you cited DEIABL243 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Muriglan, SJ; Ramirez-Montagut, T; et al. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. JOURNAL OF EXPERIMENTAL MEDICINE 200:149-157(2004).
Londero, D; Rinaldi, C; et al. Detection of platelet auto- and allo-antibodies using solid phase red cell adherence assay with a fully automated system. TRANSFUSION 48:168A-169A(2008).